Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

"Cancer patients who smoke would clearly benefit if GPs became more actively involved in offering support to quit smoking." - Professor Paul Aveyard, University of Oxford

Lung cancer survivors who quit smoking within a year of diagnosis will live for longer than those who continue to smoke, according to new research led by the Universities of Oxford and Birmingham.

The findings also revealed that general practitioners are comparatively less likely to intervene and offer stop-smoking support to cancer patients, than they are to people diagnosed with coronary heart disease. This juxtaposition has resulted in lower quit rates among cancer patients.

The study, conducted in collaboration with the University of Nottingham and funded by the NIHR School for Primary Care Research, calls for better support for cancer patients who need help to quit smoking in the first year following diagnosis.

Read more....

Similar stories

New Research Highlights Importance of Early Years Development on Future Wellbeing

Oxford researchers involved nearly 4,000 children across the UK in three specially developed science lessons to educate pupils about brain development during early childhood. The SEEN (Secondary Education around Early Neurodevelopment) project was commissioned and funded by KindredSquared and is part of a wider drive to increase public understanding of how early experiences can shape the adults we become.

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.

Overusing antibiotics? Find out with Antibiotic Footprint Calculator

To help reduce the overuse of antibiotics, Oxford researchers today released a new, easy to use online tool – Antibiotic Footprint Calculator – that could make an important contribution in the fight against antimicrobial resistance (AMR), one of the world’s most significant emerging threats to public health.